ZIOPHARM Oncology Inc (ZIOP) has risen sharply, recording gains of 8.23% in the past 4 weeks. However, the stock has corrected -9.62% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 8.46% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 1.87% and the fifty day Moving Average is 3.17%. ZIOPHARM Oncology, Inc. has dropped 28.82% during the last three month period . Year-to-Date the stock performance stands at -36.7%.
ZIOPHARM Oncology Inc (ZIOP) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $21 and the lowest price target forecast is $7. The average forecast of all the analysts is $14 and the expected standard deviation is $9.9.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP): stock turned positive on Friday. Though the stock opened at $5.12, the bulls momentum made the stock top out at $5.4 level for the day. The stock recorded a low of $5.1 and closed the trading day at $5.26, in the green by 1.74%. The total traded volume for the day was 1,453,449. The stock had closed at $5.17 in the previous days trading.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. The Companys pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Companys clinical stage product candidate, Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12, or IL-12, a potent, naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex, for the treatment of metastatic melanoma, and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).